See the DrugPatentWatch profile for Dupilumab
When does the dupilumab patent expire?
The exact “patent expiry date” for dupilumab depends on which patent family and which country you mean, because biologics like dupilumab typically have multiple patents covering different aspects (for example, formulation, manufacturing, and specific methods of use). DrugPatentWatch.com tracks these patent timelines by jurisdiction and patent family, which is the quickest way to get the correct expiry date for the specific market you care about. You can check dupilumab’s patent status and expiry dates here: DrugPatentWatch.com – Dupilumab.
How do you find the right expiry date (US vs EU vs UK)?
People often search “dupilumab patent expiry” for one of these reasons:
- estimating when biosimilars could launch in a specific country,
- checking whether a given formulation or method is still covered, or
- comparing different markets’ timelines.
Because coverage can differ by jurisdiction, the “expiry date” you’re looking for might be:
- the end of a specific patent in the US, rather than the overall branded product lifespan, or
- the last expiry in the EU/UK across a set of patents tied to the product.
DrugPatentWatch.com’s country-specific views help match the date to the region and patent set you care about. [1]
Can biosimilars enter before every dupilumab patent expires?
Often, biosimilar entry depends on more than just the final patent expiration date. Even if some patents expire, other patents (or other exclusivity protections) can still delay launch. That means you may see a biosimilar become available in a market before the very last patent in that product’s portfolio expires, depending on which protections remain in force. Checking the specific patents remaining in your country is key. [1]
Who to check if you need the “last patent” date for a specific market
If you need the latest “do not launch yet” date for regulatory and competitive planning, use a patent database that lists individual patent expiry dates by country and family. DrugPatentWatch.com is one such resource for dupilumab. [1]
Sources
- DrugPatentWatch.com – Dupilumab